Ongoing important trials
IMPACT — mitomycin PIPAC in unresectable appendiceal/CRC peritoneal metastases
Investigation of Mitomycin C PIPAC - FOLFIRI Combination for Unresectable Appendiceal or Colorectal Peritoneal Metastases Treatment (IMPACT)
- Phase
- Phase III
- Recruitment
- Recruiting
- Results maturity
- No results
- Publication
- No publication
- Regulatory approval
- No regulatory approval
- NCT
- NCT07271355
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? When peritoneal spread cannot be surgically removed, a trial tests aerosolized chemotherapy inside the abdomen.
Why promising? Tests PIPAC against systemic therapy at randomized phase III level in unresectable peritoneal disease.
What is not proven? No efficacy/safety results yet; not standard care.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
Phase III; recruiting (City of Hope). No results yet.
Cancer / population: Peritoneal metastasis, Colon — Unresectable apendiks veya kolorektal peritoneal metastaz
Intervention: Mitomycin PIPAC + FOLFIRI (± bevacizumab bağlamı çalışma tasarımına göre)
Primary endpoint: Protokol tanımlı primer etkinlik (CT.gov)
Limitations: Yeni faz III; merkez deneyimi kritik.